

Joseph Cheriyan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/919368/publications.pdf>

Version: 2024-02-01

89
papers

2,299
citations

236612

25
h-index

223531

46
g-index

96
all docs

96
docs citations

96
times ranked

3654
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-Tumor Necrosis Factor- α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2012, 126, 2473-2480.	1.6	196
2	Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist. <i>Hypertension</i> , 2015, 65, 834-840.	1.3	131
3	Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 911-922.	2.3	123
4	Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 971-979.	1.1	122
5	Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. <i>Journal of Hypertension</i> , 2013, 31, 77-85.	0.3	101
6	Effects of Oral Lycopene Supplementation on Vascular Function in Patients with Cardiovascular Disease and Healthy Volunteers: A Randomised Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e99070.	1.1	101
7	Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide-Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia. <i>Circulation</i> , 2011, 123, 515-523.	1.6	88
8	Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 335-342.	1.0	88
9	Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. <i>BMJ Open</i> , 2018, 8, e022452.	0.8	83
10	Aldehyde Dehydrogenase 2 Plays a Role in the Bioactivation of Nitroglycerin in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1891-1895.	1.1	82
11	Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 155-165.	1.0	76
12	An Approximation Algorithm for the Minimum-Cost k-Vertex Connected Subgraph. <i>SIAM Journal on Computing</i> , 2003, 32, 1050-1055.	0.8	69
13	The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. <i>Journal of Hypertension</i> , 2009, 27, 1784-1788.	0.3	62
14	Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. <i>Chest</i> , 2017, 151, 555-563.	0.4	62
15	The role of epoxyeicosatrienoic acids in the cardiovascular system. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 28-44.	1.1	57
16	Quantification of Lung PET Images: Challenges and Opportunities. <i>Journal of Nuclear Medicine</i> , 2017, 58, 201-207.	2.8	55
17	Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. <i>International Journal of Cardiology</i> , 2008, 129, 399-405.	0.8	46
18	[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. <i>Frontiers in Neuroscience</i> , 2017, 11, 92.	1.4	46

#	ARTICLE	IF	CITATIONS
19	The Role of the Autonomic Nervous System in the Regulation of Aortic Stiffness. <i>Hypertension</i> , 2016, 68, 1290-1297.	1.3	44
20	Anti-IL-6 receptor α 1 monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double-blind, placebo-controlled study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 304-315.	1.1	36
21	Repurposed immunomodulatory drugs for Covid-19 in pre-ICU patients - multi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 626.	0.7	32
22	Increased Incidence of Interatrial Block in Younger Adults with Cryptogenic Stroke and Patent Foramen Ovale. <i>Cerebrovascular Diseases Extra</i> , 2011, 1, 36-43.	0.5	31
23	Niclosamide – A promising treatment for COVID-19. <i>British Journal of Pharmacology</i> , 2022, 179, 3250-3267.	2.7	31
24	Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 799-806.	1.1	30
25	Approximation Algorithms for Network Design with Metric Costs. <i>SIAM Journal on Discrete Mathematics</i> , 2007, 21, 612-636.	0.4	29
26	Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease. <i>Hypertension</i> , 2018, 71, 499-506.	1.3	29
27	Randomized $O(M(V))$ Algorithms for Problems in Matching Theory. <i>SIAM Journal on Computing</i> , 1997, 26, 1635-1655.	0.8	28
28	Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1127-1142.	1.2	27
29	Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 99-106.	1.1	24
30	Quantitative analysis of dynamic ^{18}F -FDG PET/CT for measurement of lung inflammation. <i>EJNMMI Research</i> , 2017, 7, 47.	1.1	23
31	Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018, 19, 100.	1.4	23
32	The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. <i>PLoS ONE</i> , 2018, 13, e0194197.	1.1	23
33	Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	20
34	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 92-96.	0.9	19
35	GLP-1 Is a Coronary Artery Vasodilator in Humans. <i>Journal of the American Heart Association</i> , 2018, 7, e010321.	1.6	16
36	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. <i>Scientific Reports</i> , 2019, 9, 19934.	1.6	14

#	ARTICLE	IF	CITATIONS
37	muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 690.	0.7	14
38	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 49.	0.7	14
39	Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. <i>PLoS ONE</i> , 2020, 15, e0228940.	1.1	13
40	Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibitionâ€“Induced Hypertension. <i>Hypertension</i> , 2021, 77, 1591-1599.	1.3	13
41	Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease. <i>Age and Ageing</i> , 2021, 50, 795-801.	0.7	12
42	Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease. , 2022, 1, .		12
43	A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparlsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension programâ€”AIM-HY INFORM trial. <i>American Heart Journal</i> , 2018, 204, 102-108.	1.2	11
44	The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 518-523.	1.1	10
45	Advances in PET to assess pulmonary inflammation: A systematic review. <i>European Journal of Radiology</i> , 2020, 130, 109182.	1.2	10
46	Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (â€“EVOLUTIONâ€™): Rationale and protocol. <i>Artery Research</i> , 2014, 8, 24.	0.3	9
47	Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. <i>Thorax</i> , 2018, 73, 1182-1185.	2.7	9
48	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102035.	1.1	9
49	Role of increased aortic stiffness in the pathogenesis of heart failure. <i>Current Heart Failure Reports</i> , 2007, 4, 121-126.	1.3	8
50	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1701-1707.	2.8	8
51	THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION. <i>Journal of the American College of Cardiology</i> , 2021, 77, 159.	1.2	8
52	Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study. <i>BMJ Open</i> , 2020, 10, e038360.	0.8	8
53	Baricitinib set to join the Covid-19 therapeutic arsenal?. <i>Rheumatology</i> , 2021, 60, 1585-1587.	0.9	7
54	Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0094.	0.9	7

#	ARTICLE	IF	CITATIONS
55	An O (VE) algorithm for ear decompositions of matching-covered graphs. ACM Transactions on Algorithms, 2005, 1, 324-337.	0.9	6
56	Non-invasive measurements of arterial function: What? When? Why should we use them?. Heart, 2019, 105, heartjnl-2018-312970.	1.2	6
57	Left atrial mechanics and aortic stiffness following high intensity interval training: a randomised controlled study. European Journal of Applied Physiology, 2020, 120, 1855-1864.	1.2	5
58	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. BMJ Open, 2021, 11, e037457.	0.8	4
59	Reproducibility of compartmental modelling of 18F-FDG PET/CT to evaluate lung inflammation. EJNMMI Physics, 2019, 6, 26.	1.3	4
60	Value of haemodynamic profiling to the response of antihypertensive therapy. Artery Research, 2014, 8, 189.	0.3	3
61	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Frontiers in Pharmacology, 2020, 11, 580560.	1.6	3
62	The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers in Pharmacology, 2018, 9, 1301.	1.6	2
63	ChemoPROphyLaxls with hydroxychloroquine For covid-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 604.	0.7	2
64	Quantitative ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Research, 2021, 7, 00699-2020.	1.1	2
65	Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study. ESC Heart Failure, 2021, 8, 4562-4571.	1.4	2
66	Primary prevention of CVD: treating hypertension. Clinical Evidence, 2010, 2010, .	0.2	2
67	Abstract 18188: Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (A1ATD) are Associated With Increased Aortic Inflammation and Stiffness. Circulation, 2015, 132, .	1.6	2
68	3.2 A COMPARISON OF THE VICORDER APPARATUS WITH SPHYGMOCOR DEVICE FOR THE NON-INVASIVE ASSESSMENT OF AORTIC BLOOD PRESSURE: AN INVASIVE VALIDATION STUDY. Artery Research, 2010, 4, 146.	0.3	1
69	Response to Letter Regarding Article, "Tumor Necrosis Factor- α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis" Circulation, 2013, 128, e11.	1.6	1
70	S124...The BODE Index is an independent determinant of arterial stiffness in Chronic Obstructive Pulmonary Disease (COPD): Abstract S124 Table 1. Thorax, 2015, 70, A70.2-A71.	2.7	1
71	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers " a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. Journal of Drug Assessment, 2019, 8, 167-174.	1.1	1
72	Safety and pharmacology of a soluble epoxide hydrolase inhibitor. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
73	P1.06 THE ACCURACY OF CENTRAL SYSTOLIC BLOOD PRESSURE DETERMINED FROM THE SECOND SYSTOLIC PEAK OF THE PERIPHERAL PRESSURE WAVEFORM. <i>Artery Research</i> , 2009, 3, 162.	0.3	0
74	103â€¦Aortic inflammation is reduced, and parallels changes in aortic stiffness by anti-TNF \pm therapy in rheumatoid arthritis. <i>Heart</i> , 2012, 98, A59.2-A59.	1.2	0
75	P4.03 ORAL LYCOPENE SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE: A RANDOMISED CONTROLLED TRIAL. <i>Artery Research</i> , 2012, 6, 183.	0.3	0
76	Comparison of analysis approaches for multi-level vascular imaging data. <i>Trials</i> , 2015, 16, .	0.7	0
77	1.6 THE BODE INDEX PROGNOSTIC SCORE IS AN INDEPENDENT DETERMINANT OF ARTERIAL STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). <i>Artery Research</i> , 2015, 12, 40.	0.3	0
78	P7.14 SERUM INFLAMMATORY MARKERS ARE POOR PREDICTORS OF VASCULAR INFLAMMATION AND VASCULAR INFLAMMATION DOES NOT DETERMINE AORTIC STIFFNESS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). <i>Artery Research</i> , 2015, 12, 33.	0.3	0
79	12.6 THE ROLE OF NEURONAL NITRIC OXIDE SYNTHASE IN YOUNG ADULTS. <i>Artery Research</i> , 2016, 16, 78.	0.3	0
80	P29 MECHANISMS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION INDUCED HYPERTENSION. <i>Artery Research</i> , 2018, 24, 87.	0.3	0
81	Chapter 1 Aetiology and pathophysiology. , 2009, , .		0
82	Chapter 4 Secondary hypertension. , 2009, , .		0
83	Chapter 6 Special populations. , 2009, , .		0
84	Chapter 8 Hypertension in the 21st century. , 2009, , .		0
85	Chapter 3 Specific investigations for secondary hypertension. , 2009, , .		0
86	Chapter 5 Monogenic syndromes. , 2009, , .		0
87	A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients. , 2016, , .		0
88	A functional imaging study to evaluate aortic inflammation in OSA subjects. , 2016, , .		0
89	Late Breaking Abstract - Co-morbid disease clusters in chronic obstructive pulmonary disease: the ERICA study. , 2017, , .		0